![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Introduction: Pathological antibody production by B lymphocytes is characteristic of numerous primary and secondary glomerular diseases of the kidney. Specific and less toxic therapies that target antibody-producing B cells are therefore needed. Based on its property of selectively depleting CD20+ B cells, rituximab is a therapeutic option for antibody-mediated kidney diseases and adds to the existing drug armamentarium for the treatment of a number of these disorders.
Areas covered: This article reviews the current use of rituximab in renal disease and transplantation, and includes discussion of the drug's potential role in conditions where traditional treatment has failed. A literature search using PubMed data base was undertaken using search words rituximab and kidney transplantation, glomerulonephritis, antibody production etc.
Expert opinon: Rituximab could be a beneficial drug in certain renal diseases and for complications related to kidney transplantation where conventional treatment has not been successful.
Notes
This box summarizes key points contained in the article.